Spartalizumab (PDR001) is a humanized immunoglobulin G4 monoclonal antibody that selectively binds to PD-1 at low concentrations, exhibiting high activity. It blocks the interaction with PD-L1 and PD-L2, making it suitable for studying undifferentiated thyroid cancer (ATC).
Purity:
95.10%
CAS Number:
[1935694-88-4]
Target:
PD-1/PD-L1
* VAT and and shipping costs not included. Errors and price changes excepted
